New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
08:58 EDTACORAcorda Therapeutics delays start of Phase 3 study of dalfampridine-QD to 2H
Acorda Therapeutics announced that the initiation of its Phase 3 study of dalfampridine-QD in people with post-stroke walking deficits will begin in the second half of 2014; previously the company had projected study initiation in the second quarter of 2014. The developer of the once-daily, or QD, formulation has informed the company of an alcohol dose dumping finding in vitro and the company will need to perform a short clinical study to determine whether this also exists in vivo. The clinical study will be conducted in healthy volunteers and is expected to be completed in the third quarter of 2014, Acorda said.
News For ACOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
06:07 EDTACORAcorda Therapeutics sees FY16 Ampyra revenue $475M-$485M
Subscribe for More Information
06:06 EDTACORAcorda Therapeutics reports Q4 Ampyra net revenue up 11% y-o-y to $122M
Subscribe for More Information
06:05 EDTACORAcorda Therapeutics reports Q4 non-GAAP EPS 28c, consensus 22c
Reports Q4 revenue $130.90M, consensus $128.24M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use